global
pandem
begun
oversatur
world
medic
capac
accommod
larg
surg
patient
acut
respiratori
distress
syndrom
ard
acut
respiratori
distress
syndrom
effect
treatment
besid
support
care
use
ventilatori
strategi
encompass
low
tidal
volum
limit
transpulmonari
pressur
mainstay
consist
find
ard
deposit
fibrin
airspac
lung
parenchyma
along
fibrinplatelet
microthrombi
pulmonari
vasculatur
contribut
develop
progress
respiratori
dysfunct
right
heart
failur
similar
patholog
find
observ
lung
specimen
patient
infect
physiolog
destruct
activ
clot
system
ard
result
enhanc
activ
propag
clot
format
togeth
suppress
fibrinolysi
thought
mediat
dysfunct
pulmonari
endothelium
case
influenza
target
coagul
fibrinolyt
system
improv
treatment
ard
propos
sinc
least
particular
use
plasminogen
activ
limit
ard
progress
reduc
ardsinduc
death
receiv
strong
support
anim
model
phase
human
clinic
trial
hardaway
colleagu
show
administr
either
urokinas
streptokinas
patient
termin
ard
reduc
expect
mortal
advers
bleed
event
importantli
major
patient
ultim
succumb
die
renal
hepat
failur
rather
pulmonari
failur
recent
american
hospit
associ
assess
indic
patient
may
requir
mechan
ventil
fullyfeatur
ventil
current
avail
base
survey
estim
mortal
rate
critic
ill
patient
infect
use
statist
earli
report
hubei
provinc
taken
togeth
statist
indic
emerg
need
effect
therapeut
treat
attenu
ard
secondari
particularli
salvag
patient
decompens
respiratori
statu
access
mechan
ventil
extracorpor
membran
oxygen
ecmo
posit
administr
tissu
plasminogen
activ
tpa
compassion
salvag
approach
may
merit
situat
consider
therapi
wide
avail
recogn
indic
tradit
consid
highrisk
fibrinolyt
agent
warrant
unpreced
public
health
emerg
sinc
risk
advers
event
tpa
far
outweigh
certainti
death
patient
meet
elig
criteria
treatment
prior
studi
hardaway
et
al
evalu
fibrinolyt
therapi
treatment
ard
use
urokinas
streptokinas
contemporari
approach
thrombolyt
therapi
involv
use
tpa
due
higher
efficaci
clot
lysi
compar
bleed
risk
fibrinolyt
agent
addit
tpa
treatment
report
greater
reduct
death
larger
increas
arteri
po
larger
decreas
arteri
pco
compar
untreat
control
either
urokinaseplasminogen
activ
upa
plasmin
comprehens
metaanalysi
anim
studi
acut
lung
injuri
although
none
studi
includ
viralinduc
ard
dose
rout
administr
durat
treatment
remain
defin
model
effort
individu
interest
approach
need
underway
anim
model
acut
lung
injuri
intratrach
intraven
dose
fibrinolyt
agent
effect
nebul
deliveri
base
larg
bodi
experi
use
tpa
acut
treatment
stroke
myocardi
infarct
administr
may
easiest
implement
howev
unlik
brief
treatment
use
situat
defin
nidu
clot
present
without
ongo
widespread
disrupt
hemostat
system
believ
initi
approach
might
administ
mg
tpa
hour
follow
tpa
infus
administ
subsequ
hour
dose
exceed
mgkg
exclus
criteria
current
place
stroke
mi
treatment
could
use
respond
maintain
period
heparin
infus
complet
tpa
treatment
exactli
patient
would
qualifi
salvag
treatment
similarli
remain
defin
patient
ard
ratio
less
pco
greater
despit
prone
posit
maxim
mechan
ventilatori
support
would
seem
ideal
candid
particularli
set
ecmo
possibl
furthermor
scenario
mechan
ventil
capac
may
appropri
progress
pulmonari
deterior
extraordinari
time
may
call
extraordinari
measur
observ
trial
treatment
first
seri
patient
effect
safe
approach
could
readili
broaden
would
multipl
patientrel
public
health
benefit
includ
earlier
wean
ventil
free
ventil
patient
need
prevent
patient
progress
need
ecmo
support
like
limit
resourcelimit
crisi
leverag
avail
modest
cost
wide
preexist
clinic
familiar
tpa
author
declar
conflict
interest
